|

Irinotecan Clinical Trials

75 actively recruiting trials across 25 locations

▼ -2 trials since May 2026

Also known as: CAMPTOSAR, CPT-11, Campto, Camptosar, Camptothecin-11 +10 more

Pipeline

Phase 1: 16Phase 2: 24Phase 3: 17Phase 1/2: 16

Top Sponsors

  • Fudan University3
  • Children's Oncology Group3
  • Astellas Pharma Global Development, Inc.3
  • Sun Yat-sen University2
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2

Indications

Other30 trials

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Phase 1/2
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
Phase 1
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Phase 1/2
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Phase 3
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3
A Study of TXN10128 in Subjects With Solid Tumors
Phase 1
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Phase 3
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
Phase 2
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
Phase 2
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Phase 2
Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS
Phase 2
Efficacy of Hyperthermic Intraperitoneal Chemotherapy
Phase 3
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Phase 2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Phase 1/2
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Phase 2
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
Phase 3
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Phase 2
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Phase 3
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
Phase 2
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
Phase 1/2
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Phase 1/2
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
Phase 3
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Phase 3
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Phase 2
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
Phase 2
The Sagittarius Trial
Phase 3
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
Phase 2

Birmingham, Alabama11 trials

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Childrens Hospital of Alabama

Phase 2
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Children's Hospital of Alabama

Phase 3
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

University of Alabama at Birmingham

Phase 1/2
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

O Neal Comprehensive Cancer Center at UAB

Phase 1/2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Children's Hospital of Alabama

Phase 2
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Children's Hospital of Alabama

Phase 3
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

University of Alabama at Birmingham (Children's of Alabama)

Phase 1
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

University of Alabama/Children's of Alabama

Phase 1/2
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

University of Alabama at Birmingham Cancer Center

Phase 3
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Children's Hospital of Alabama

Phase 1/2
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

University of Alabama at Birmingham Cancer Center

Phase 3

Duarte, California3 trials

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

City of Hope

Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

City of Hope Medical Center

Phase 1

Orange, California3 trials

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

University of California Irvine Medical Center

Phase 1
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Research Site

Phase 2
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 1

Chicago, Illinois3 trials

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Ann & Robert H. Lurie Children's Hospital of Chicago

Phase 2
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

The University of Chicago

Phase 1
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Ann & Robert H. Lurie Children's Hospital of Chicago

Phase 1/2

Anchorage, Alaska2 trials

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Anchorage Associates in Radiation Medicine

Phase 2
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Anchorage Associates in Radiation Medicine

Phase 3

Baltimore, Maryland2 trials

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Sidney Kimmel Comprehensive Cancer Center

Phase 2
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center

Phase 2

Boston, Massachusetts2 trials

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Massachusetts General Hospital

Phase 1
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Boston Children's Hospital

Phase 1

Houston, Texas2 trials

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

M D Anderson Cancer Center

Phase 1
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

M D Anderson Cancer Center

N/A

Chandler, Arizona1 trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Ironwood Cancer and Research Center

Phase 3

Phoenix, Arizona1 trial

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Local Institution - 0005

Phase 2

Scottsdale, Arizona1 trial

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

HonorHealth Research Institute

Phase 1

Tucson, Arizona1 trial

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)

Phase 1/2

Fullerton, California1 trial

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton

Phase 3

Los Angeles, California1 trial

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Children's Hospital Los Angeles

Phase 2

San Diego, California1 trial

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Investigative Site #101

Phase 1

San Francisco, California1 trial

Combination Therapy in Cancers With Mutations in DNA Repair Genes

University of California, San Francisco

Phase 1

Gainesville, Florida1 trial

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

University of Florida

Phase 2

Miami, Florida1 trial

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

University of Miami

Phase 1

Lexington, Kentucky1 trial

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

University of Kentucky

N/A

Rochester, Minnesota1 trial

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Mayo Clinic in Rochester

Phase 2

St Louis, Missouri1 trial

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Washington University School of Medicine

Phase 1/2

Buffalo, New York1 trial

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Roswell Park Cancer Institute

Phase 1/2

New York, New York1 trial

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2

Columbus, Ohio1 trial

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Nationwide Children's Hospital

Phase 1/2

Philadelphia, Pennsylvania1 trial

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.